BDRX vs. SBFM, SPRC, EVFM, CMRA, EVLO, BLPH, GRI, PBLA, HSTO, and ADTX
Should you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Sunshine Biopharma (SBFM), SciSparc (SPRC), Evofem Biosciences (EVFM), Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), Bellerophon Therapeutics (BLPH), GRI Bio (GRI), Panbela Therapeutics (PBLA), Histogen (HSTO), and Aditxt (ADTX). These companies are all part of the "pharmaceutical preparations" industry.
Biodexa Pharmaceuticals (NASDAQ:BDRX) and Sunshine Biopharma (NASDAQ:SBFM) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, community ranking, profitability and risk.
17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Comparatively, 14.7% of Sunshine Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Biodexa Pharmaceuticals and Sunshine Biopharma both received 1 outperform votes by MarketBeat users.
Biodexa Pharmaceuticals has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500.
Biodexa Pharmaceuticals has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -18.70%. Biodexa Pharmaceuticals' return on equity of 0.00% beat Sunshine Biopharma's return on equity.
In the previous week, Biodexa Pharmaceuticals had 4 more articles in the media than Sunshine Biopharma. MarketBeat recorded 6 mentions for Biodexa Pharmaceuticals and 2 mentions for Sunshine Biopharma. Sunshine Biopharma's average media sentiment score of 0.50 beat Biodexa Pharmaceuticals' score of 0.46 indicating that Sunshine Biopharma is being referred to more favorably in the news media.
Sunshine Biopharma has higher revenue and earnings than Biodexa Pharmaceuticals.
Biodexa Pharmaceuticals currently has a consensus price target of $8.00, suggesting a potential upside of 515.38%. Sunshine Biopharma has a consensus price target of $260.00, suggesting a potential upside of 27,268.42%. Given Sunshine Biopharma's higher possible upside, analysts plainly believe Sunshine Biopharma is more favorable than Biodexa Pharmaceuticals.
Summary
Biodexa Pharmaceuticals and Sunshine Biopharma tied by winning 6 of the 12 factors compared between the two stocks.
Get Biodexa Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodexa Pharmaceuticals Competitors List
Related Companies and Tools
